Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer

Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT pr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Palmieri, Carlo, Macpherson, Iain RJ, Yan, Kelvin, Ades, Felipe, Riddle, Pippa, Ahmed, Riz, Owadally, Waheeda, Stanley, Barbara, Shah, Deep, Gojis, Ondrej, Januszewski, Adam, Lewanski, Conrad, Asher, Rebecca, Lythgoe, Daniel, de Azambuja, Evandro, Beresford, Mark, Howell, Sacha J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2015
Pynciau:
Clinical Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914352/
https://ncbi.nlm.nih.gov/pubmed/26334099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.4801
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg